Topical piezo-print technology could solve many of the problems associated with use of topical eye medications– and ultimately change the game in myopic progression
Sean Ianchulev | | Longer Read
At a Glance
- The incidence of myopia is increasing, but so too is the more pathological form of the condition: myopic progression
- FDA-approved treatments for myopic progression are not yet available, but low-dose atropine drops can have a significant impact on patient outcomes
- Topical administration of atropine eyedrops may result in either over- or under-dosing of the medication.
- Eyenovia’s atropine solution (MicroPine) is formulated for administration using the OpteJet microdose dispenser, which is designed to deliver medication as a gentle mist reaching the eye faster than the blink reflex. The dispenser’s built-in electronic monitoring system also encourages compliance thanks to its in-build electronic monitoring system.
I have spent my career on the front line of retinal therapy and, a decade ago, we introduced Lucentis at Genentech – a biologic for wet AMD which completely transformed AMD management – it was, if you like, a “penicillin moment.” I now believe that we are approaching another step change in patient care, but for an entirely different condition – myopic progression.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.